Last reviewed · How we verify
C. CNS 7056
At a glance
| Generic name | C. CNS 7056 |
|---|---|
| Also known as | CAS No. 1001415-66-2, Remimazolam |
| Sponsor | Paion UK Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy (NA)
- The Impact of Remimazolam Tosilate on Oxygenation and Postoperative Cognitive Function in Elderly Patients Undergoing Thoracoscopic Lobectomy (PHASE1, PHASE2)
- Relationship Between Remimazolam and Etomidate in Induction of General Anesthesia (EARLY_PHASE1)
- The Application of Remazolam in Gastroenteroscopy (NA)
- Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients (PHASE1)
- The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation (PHASE4)
- 95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment (NA)
- A Trial of Efficacy and Safety of Remimazolam Tosilate for Injection in Local Anesthesia Assisted Sedation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C. CNS 7056 CI brief — competitive landscape report
- C. CNS 7056 updates RSS · CI watch RSS
- Paion UK Ltd. portfolio CI